Search results for "Atrial fibrillation"
Non-aspirin NSAIDs associated with risk for atrial fibrillation or flutter, study finds
Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors may be associated with increased risk for atrial fibrillation or flutter, according to a new study.
https://immattersacp.org/weekly/archives/2011/07/12/2.htm
12 Jul 2011
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://immattersacp.org/archives/2022/04/latest-updates-on-acps-priorities-initiatives.htm
1 Apr 2022
Use of warfarin down, DOACs up in commercially insured patients with cirrhosis, nonvalvular afib
While more than half of eligible patients with cirrhosis and concurrent nonvalvular atrial fibrillation did not receive anticoagulation between 2012 and 2019, use of direct oral anticoagulants (DOACs) increased substantially during that time, a recent study found.
https://immattersacp.org/weekly/archives/2023/01/17/4.htm
17 Jan 2023
Apixaban safer, more effective than rivaroxaban for afib with heart disease, study finds
Apixaban was associated with a lower rate of ischemic stroke or systemic embolism and a lower rate of bleeding in a propensity-matched cohort study of commercially insured patients with atrial fibrillation (AF) and valvular heart disease.
https://immattersacp.org/weekly/archives/2022/10/18/2.htm
18 Oct 2022
A can't-miss cause of resistant hypertension
More than 20% of patients with resistant hypertension have primary aldosteronism, an underrecognized cause of hypertension and cardiovascular disease.
https://immattersacp.org/archives/2021/05/a-cant-miss-cause-of-resistant-hypertension.htm
1 May 2021
Diltiazem may increase bleeding risk when coadministered with DOACs in afib
A study of patients with atrial fibrillation in one U.S. health system found a 56% higher risk for bleeding-related hospitalization associated with concomitant use of diltiazem and a direct-acting oral anticoagulant (DOAC) versus a DOAC alone.
https://immattersacp.org/weekly/archives/2022/07/12/5.htm
12 Jul 2022
Big data and the bog of information
Key questions exist to adopting consumer-grade medical devices, such as how to analyze vast quantities of data in a meaningful way.
https://immattersacp.org/archives/2018/09/big-data-and-the-bog-of-information.htm
1 Sep 2018
Task Force finds insufficient evidence on screening for afib
The U.S. Preventive Services Task Force reviewed trials published since 2017 but did not deem them strong enough to show evidence of benefit or harm.
https://immattersacp.org/weekly/archives/2022/02/01/3.htm
1 Feb 2022
Risks and benefits of procedure versus medication in afib vary by individual
A modeling study found that left atrial appendage occlusion could be an alternative to oral anticoagulants in patients at high bleeding risk but that the combination of risks for stroke and bleeding should be considered on an individual basis.
https://immattersacp.org/weekly/archives/2022/08/16/4.htm
16 Aug 2022
Amiodarone increases bleeding compared with flecainide or sotalol in patients on anticoagulant therapy
A retrospective analysis of Medicare patients who started an anticoagulant and then amiodarone found that they had a 44% increased risk for bleeding-related hospitalization compared to those on other antiarrhythmics and that this risk was higher with rivaroxaban than apixaban.
https://immattersacp.org/weekly/archives/2023/05/23/1.htm
23 May 2023